{"title":"Repurposing vamifeport for lupus nephritis","authors":"Holly Webster","doi":"10.1038/s41584-026-01370-w","DOIUrl":null,"url":null,"abstract":"Preclinical findings indicate that vamifeport, an oral ferroportin inhibitor, could be used as an adjunct therapy for lupus nephritis.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"22 5","pages":"282-282"},"PeriodicalIF":33.7000,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41584-026-01370-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Preclinical findings indicate that vamifeport, an oral ferroportin inhibitor, could be used as an adjunct therapy for lupus nephritis.
期刊介绍:
Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.